AIM ImmunoTech Inc.
AMEX: AIM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas K. Equels
- Employees
- 21
- Headquarters
- Ocala, United States
- IPO year
- 1995
- Market cap
- $1.3M
- Website
- https://aimimmuno.com
Loading AIM…
Loading profile data…Frequently asked questions about AIM
What does AIM ImmunoTech Inc. (AIM) do?
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid...
Where does AIM trade?
AIM ImmunoTech Inc. (AIM) trades on the New York Stock Exchange American.
What sector is AIM in?
AIM ImmunoTech Inc. (AIM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AIM ImmunoTech Inc.?
Thomas K. Equels is the chief executive officer of AIM ImmunoTech Inc. (AIM).
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc. is headquartered in United States.
Does AIM pay a dividend?
AIM ImmunoTech Inc. (AIM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AIM go public?
AIM ImmunoTech Inc. (AIM) completed its initial public offering in 1995.